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2013.02.0Abstract Tobacco smoking is one of the most potent and prevalent addictive habits, inﬂuencing
the behavior of human beings for over four centuries. It is not surprising that immunological studies
on the effect of cigarette smoking on the human immune system are rather rare. This cross-
sectional, parallel group study was performed at the King Khaled Hospital between May and
November 2010. Thirty current smokers (16 males and 14 females), aged 18–41 years were included.
The level of IFN-c, IgG and IgM in serum along with the T-lymphocyte subset (CD4+, CD8+ and
CD16+) percentage was assessed. Systemic exposure to nicotine was assessed by a radioimmunoas-
say (RIA) with a double antibody for cotinine. The results revealed a decrease in the total leukocyte
count, decrease in the CD4+ levels with a signiﬁcant decrease of CD4+/CD8+ ratio along with a
decrease in natural killer CD16+ level of both groups of cigarette smokers and a signiﬁcant decrease
in the IgG level and increase in the IFN-c level. The ﬁndings suggest that CD4+, CD8+, CD16+,
IgG, IgM and IFN-c are sensitive to the cumulative chronic effect of smoking because they can
affect both innate and adaptive immunity and may serve as a potential immuno-biomarker for
active smoking. The current review underlines the importance of smoking prevention and eradica-
tion not only for its ordinary disorders but also for its autoimmune disorders as well.
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031. Introduction
Immunotoxicity is an adverse response of the immune system
to chemicals or drugs which may result in disease1 and it is a
relatively new ﬁeld of investigation that is being recognized
and used by toxicologists involved in the study of drugs and
chemical exposure.2 The immunosuppressive effects associated
with prolonged exposure to chemical substances are often
accompanied by an increased susceptibility to challenge with
infectious agents and certain forms of neoplasia.3 Cigarette
smoke is an extremely complex mixture, containing thousands
of individual chemicals, among which are polycyclic aromaticorensic Medicine Authority.
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benzene, catechols and radioisotopes.4 Tobacco smoking is
one of the most potent and prevalent addictive habits, inﬂu-
encing the behavior of human beings for over four centuries.5
According to WHO (2008) there are currently more than one
billion smokers in the world and on average, smokers lose
about 10 years of life and worldwide annual deaths from to-
bacco is likely to rise to 10 million per year and 100 million
per decade by 2030. Tobacco smoke affects multiple organ sys-
tems and results in numerous tobacco-induced diseases. The
well known health risks of tobacco smoking especially relate
to the respiratory tract and the cardiovascular system and it
inﬂuences the immune system in many ways. Many systemic
chronic conditions are likely to result from the indirect conse-
quences of continual exposure to the chemicals in cigarette
smoke, resulting in inﬂammatory reactions to the oxidative
stress and effects of smoking. In addition, smokers have in-
creased vulnerability to several infections and are predisposed
to allergic airway diseases.6 It is not surprising that immuno-
logical studies on the effect of cigarette smoking on the human
immune system are rather rare. The genotoxic effects of ciga-
rette smoking on lymphocytes and various quantitative and
functional changes in lymphocyte subpopulations were fre-
quently observed.3 Burning cigarettes produce as much as
6000 different components in addition to nicotine, including
polycyclic aromatic hydrocarbons, tobacco glycoprotein and
some metals, many of which are known to be antigenic, cyto-
toxic, mutagenic, or carcinogenic, and most of them are gener-
ated by the burning tobacco.5 Smoking is the leading cause of
preventable morbidity and mortality in the developed world,7
and are likely higher than currently acknowledged, due to
the largely unknown impact of smoking8 still over 1.1 billion
people continue to smoke, representing one sixth of the world’s
population.9
The study was conducted to investigate the probable inﬂu-
ence of cigarette smoking as a toxic compound on the immune
response.
2. Materials and methods
According to standard ethics drawn by the King Saud Univer-
sity ethics committee for human researches, this cross-sec-
tional, parallel group study was performed at the King
Khaled Hospital between May and November 2010. Thirty
current smokers (16 males and 14 females), aged 18–41 years
(25.46 ± 0.73) were selected according to reported no history
of medical or mental illness and who were not taking over-
the-counter or prescribed medications and the purpose of the
study was explained to the participants and their informed ver-
bal consent was taken. Smoking status was estimated byTable 1 The effect of cigarette smoking on mean absolute levels of
The variable Non-smokers
(N= 30)
WBC count (cell/mm3) X ± SE 9000 ± 279
By comparing between the mean values of WBC count there is a signiﬁca
the control group. Also group 2 shows a signiﬁcant decrease when comp
a p< 0.05 compared to the control group.
b p< 0.05 compared to group 1.number of cigarettes smoked per day and smoking years, cig-
arette smokers who smoked at least 11 cigarettes a day with no
prior quit attempts were chosen to reduce the possible con-
founds. Performa was ﬁlled to obtain information on previous
medical and occupational history. Thirty healthy nonsmoker
volunteer (17 males, 13 females) participants were included
as control for comparison and reported no history of cigarette
smoking, tobacco use, or over-the-counter nicotine use for at
least 5 years prior and has no chronic diseases or under medi-
cal treatments that is known or thought to inﬂuence the re-
sults. Women participants were excluded if they were
currently taking oral contraceptives, had irregular menstrual
cycles, premenstrual mood disorders, or pregnancy within
the last year. The smokers were divided into two groups: group
1 consists of 16 subjects aged 18–27 years (mean = 21.5 years)
smoking cigarettes for not more than 10 years (mean = 6.3
years) and group 2 consists of 14 subjects aged 28–41 years
(mean = 32.6 years) smoking cigarettes for more than 10 years
(mean 16.7 years). They were informed about the aims and
scope of the study and provided consent for taking blood
and urine samples (see Tables 1–4).
All subjects provided 10 ml sample of venous blood, all
samples were taken between 7 am and 10 am. Serum was sep-
arated, frozen and stored at 20 C for Igs analysis. The chem-
ical analysis was performed at the Technical Research center.
Heparinized blood was diluted 1:1 with normal saline and
overlaid on Ficoll/Paque (Biotest Co, Germany) then centri-
fuged at 400g for 30 min in room temperature. Lymphocytes
from the inter-phase were washed twice in PBS and re-
suspended to a ﬁnal concentration of 5 · 106 l11. 50 l1 sam-
ples of this suspension were incubated for 30 min at 4 C with
appropriate Boehring monoclonal antibodies (BMA 030, 040,
081 and 070) then after washing with PBS supplemented with
sodium azide anti-immunoglobulin rabbit serum labeled with
ﬂuorescein isothiocyanate was added. After 30 min of incuba-
tion, cells were washed with PBS. The percentage of T-cell sub-
populations were counted under a ﬂuorescence microscope.
The absolute number of CD4+, CD8+ and CD16+ lympho-
cytes was calculated based on the total white blood cell count
and differential white cell count. The content of IgG and IgM
in serum was assessed by radial immunodiffusion10 by using
the plates, the pack contains 12 well plates Code No.: OSLN
produced by Biocientiﬁca S.A. Biochemist-Pharmacist.
ELISA for IFN-c was done using a commercial ELISA kit
(R&D Minneapolis, MN, USA) based on the multiple anti-
body sandwich principles.11 The ELISA plates were coated
with mouse monoclonal antibody speciﬁc for human IFN-c
to capture the speciﬁc cytokine. The anti-IFN-c rabbit poly-
clonal antibody conjugated with biotin was added to the wells
followed by Streptavidine/HRP. Plates were incubated fortotal leukocytic count for all smokers and non-smokers.
Smoker group (1)
(N= 16)
Smoker group (2)
(N= 14)
6088 ± 111a 5795 ± 115a,b
nt decrease in the count in both groups 1 and 2 when compared with
ared to group 1.
Table 2 The effect of cigarette smoking on mean of speciﬁc T-lymphocyte subset percentage for all smokers and non-smokers.
The variable Non-smokers
(N= 30)
Smokers group (1)
(N= 16)
Smokers group (2)
(N= 14)
CD4+% X± SE (cell/mm3) 47.35 ± 1 43.3 ± 1 40.67 ± 1.19a,b
CD8+% X± SE (cell/mm3) 26.86 ± 1.1 30.5 ± 0.89a 36.14 ± 1a,b
CD4+/CD8 Ratio+% X± SE (cell/mm3) 1.76 ± 0.05 1.4 ± 0.04a 1.1 ± 0.03a
CD16+% X± SE (cell/mm3) 37.23 ± 1.1 31.11 ± 0.89a 27.16 ± 1.11a,b
By comparing between the CD4+% there is a decrease in both groups 1 and 2 when compared with the control group but it is non-signiﬁcant in
group 1. Also group 2 shows a signiﬁcant decrease when compared to group 1.
By comparing between the CD8+% there is a signiﬁcant increase in both groups 1 and 2 when compared with the control group. Also group 2
shows a signiﬁcant increase when compared to group 1.
By comparing between the CD4+/CD8 Ratio+% there is a signiﬁcant decrease in both groups 1 and 2 when compared to the control group.
By comparing between the CD16+% there is a signiﬁcant decrease in both groups 1 and 2 when compared with the control group. Also group 2
shows a signiﬁcant decrease when compared to group 1.
a p< 0.05 compared to the control group.
b p< 0.05 compared to group 1.
Table 3 Adjusted mean values for levels of IFN-c and immunoglobulins for all smokers and non-smokers.
The variable Non-smokers
(N= 30)
Smoker group (1)
(N= 16)
Smoker group (2)
(i = 14)
p-value
IFN-c X± SE 67.8 (49.6–82.5) 93.6 (70.3–114.5) 98.3(77.3–124.3) <0.081
IgM (g/l) X ± SE 1.4 ± 0.9 1.3 ± 0.8a 1.3 ± 0.6a <0.05
IgG (g/l) X ± SE 9.2 ± 1.1 9.1 ± 1.2 8.9 ± 2.2a,b <0.05
Igs are presented as mean ± SD.
By comparing between IFN-c there is a non-signiﬁcant increase in both groups 1 and 2 when compared to the control group.
By comparing between the IgM there is a signiﬁcant decrease in both groups 1 and 2 when compared to the control group.
By comparing between IgG there is a decrease in both groups 1 and 2 when compared with the control group but it is non-signiﬁcant in group 1,
also group 2 shows a signiﬁcant decrease when compared to group 1.
a p< 0.05 compared to the control group.
b p< 0.05 compared to group 1.
Table 4 Level of cotinine for all smokers as an indicator of cigarette smoking.
The variable Smoker group (1)
(N= 16)
Smoker group (2)
(N= 14)
p-value
Cotinine level in urine (lmol/l) 37 ± 31 39 ± 11 <0.05
50 S.M. Moustafa, A.H. El-elemi20 min. Lastly, color was developed using the peroxide/TMB
substrate solution. The substrate initiated a peroxidase cata-
lyzed color change, which was stopped within 5 min by acidi-
ﬁcation with the stop solution. Absorbance was taken with
an ELISA reader at 450 nm.
Systemic exposure to nicotine was assessed by a radioim-
munoassay (RIA) with a double antibody for cotinine; a major
metabolite of nicotine, the urine levels of which has been
shown to accurately reﬂect systemic exposure to nicotine.12
A commercially available kit, Nicotine Metabolite Double
Antibody DPC KTCD1 was used according to the instructions
of the manufacturer (Diagnostic Products Corporation, Los
Angeles, CA, USA) with the qualitative cut off for a positive
sample, i.e. 2.0 lmol/L. Subjects in the control group had to
have a concentration lower than 2.0 lmol/L.
Thereafter, data were analyzed by SPSS program and the
variability was expressed as the mean ± standard error (SE)
of the mean, the data indicating normal distribution weresubjected to statistical analysis by Student’s ‘‘t’’ test. Compar-
ison of the signiﬁcance difference between groups of patients
was determined by using analysis of variance (ANOVA)
among all groups. The p value of 60.05 was considered signif-
icant while as highly signiﬁcant at p 6 0.001.3. Discussion
Cigarette smoking continues to be the single most preventable
cause of death and illness in the United States.13 The
inﬂammatory system is kept in balance through the reciprocal
production of predominantly pro-inﬂammatory cytokines,
including interferon-gamma (IFN-c) and tumor necrosis-alpha
(TNF-a) from T helper 1 (Th1) cells and predominantly anti-
inﬂammatory cytokines, including interlukin-4-(IL4) and
interleukin 10 (IL-10) from (primarily) T helper 2 (Th2) cells.14
The present results showed a decrease in the total leukocytic
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control group. The possibility that cigarette smoke modiﬁes
risk factors and prevalence to the infectious diseases is pre-
sumed to be, in most of the cases, immunologic in nature.
However, the mechanism by which cigarette smoke changes
in the immune response remains poorly understood.4 Smoking
may depress immune function because nicotine stimulates the
hypothalamic-pituitary-adrenal axis15 thereby elevating levels
of endogenous glucocorticoids, which are powerful immuno-
suppressants in vivo16 and in vitro17 ﬁnally, tobacco-related
polycyclic aromatic hydrocarbons, such as benzo{a}pyrene,
have been implicated in the suppression of B-cell lymphopoie-
sis and cytotoxicity in lymphokine-activated killer cells.18
In a major study of lifestyle factors and health involving
2892 Japanese men and women, cigarette smoking was associ-
ated with decreased Natural killer cytotoxic activity however,
immune system functioning is inﬂuenced by other lifestyle vari-
ables, such as diet, alcohol consumption, daily workload,
sleep, body weight and psychological stress19 thus an improve-
ment in immune function after smoking cessation could result
from other lifestyle changes, which accompany smoking cessa-
tion. Smoking is the central factor in many pathological condi-
tions. Its role in neoplasm, lung and cardiovascular diseases
has been well established for years5 the present study suggested
a decrease in the CD4+ levels with signiﬁcant decrease of
CD4+/CD8+ in both smokers groups, which agreed with a
study in Poland assessing the immunological ﬁndings in ciga-
rette smoking, in which a decreasing trend in CD4+/CD8+ ra-
tio was noted.3 And these results disagree with a study in
Japan which suggested that an increase in memory CD4+ T
lymphocytes is sensitive to the cumulative effects of smoking.20
While the acute effects of cigarette smoke on the immune sys-
tem are less clear, chronic exposure to cigarette smoke or nic-
otine causes T cell unresponsiveness. This apparent T cell
anergy may account for or contribute to the immunosuppres-
sive and anti-inﬂammatory properties of cigarette smoke/nico-
tine. Nicotine induced immunosuppression may result from its
direct effects on lymphocytes, indirectly through its effects on
the neuroendocrine system, or both.21 In vitro the addition of
nicotine to T cells increased protein tyrosine kinase (PTK)
activity and intracellular CA2+ concentration. These results
support the hypothesis that nicotine alters immune responses
by directly interacting with T cells, as well as indirectly through
brain–immune interactions.22 It is difﬁcult to determine the
immunological response of smokers since the tobacco speci-
mens or cigarettes show signiﬁcant differences in the contents
of chemicals and smokers differ from each other according to
their age, sex, number of cigarettes smoked per day and the
environmental exposures from one place to another. All smok-
ers in the present study were not occupationally exposed to
chemicals, their social and economic status were extremely
similar. Although we did the best to select a homogenous pop-
ulation for this study, it is known that the numbers of lympho-
cytes can vary depending on various life conditions.
With regard to cigarette smoking and immune function,
in vitro and in vivo studies on the effects of cigarette smoking
toxins and nicotine on both IFN-c and IL-10 are inconclu-
sive. The present results mentioned an increase in the
IFN-c level but it is a non-signiﬁcant increase which agrees
with the results of the study in 2009 which revealed an
increase in IFN-c and suggested that it may be due to the
increase in the number of lymphocytes, periodontal statusand is strongly inﬂuenced by female gender and age and
not by smoking.23 A recent study reported that the cumula-
tive exposure to cigarette smoking enhances telomere shorten-
ing in circulating lymphocytes,24 suggesting the pro-aging
effect of smoking. Smokers may have difﬁculties in response
to recall antigens due to repetitive proliferation of antigen-
speciﬁc memory t lymphocytes, which may account for smok-
ers to have a higher incidence of infectious diseases compared
to non-smokers.25
Generally, it can be stated that the reports on T- and B-cell
counts as well as on immunoglobulin serum levels in smokers
are disagreeing. In a study in Poland in immunological ﬁndings
in cigarette smokers, it was shown that despite the lowered
IgA, IgG and IgM levels there was no correlation between
changes in the count of B-cells producing immunoglobulins,
and immunoglobulin levels in smokers.3 Several large studies
have shown that tobacco smokers have lower levels of immu-
noglobulins IgG and IgA.26 Which agree with the present re-
sults which showed a signiﬁcant decrease in the IgG level in
the group of smokers who smoke cigarettes for more than
10 years and decrease in IgM in both smoker groups.4. Conclusion and recommendations
Smoking has deleterious effects on the immune system causing
relative immune deﬁciency. Smoking prevention or cessation
seems to be more essential than ever.References
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